HomeProductsBuilding BlocksHeterocyclic ScaffoldsPiperazinesOlmutinib
Chemical structure of CAS 1353550-13-6

Olmutinib

In Stock•Starting at $21 for 1 mg•Purity ≥ 98%
CAS No.1353550-13-6
MDL No.MFCD29918158
MFC26H26N6O2S
MW486.60
InChI KeyFDMQDKQUTRLUBU-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98%$21In Stock
5 mg98%$24In Stock
10 mg98%$39In Stock
50 mg98%$121In Stock
100 mg98%$205In Stock
250 mg98%$346In Stock
1 g98%$970In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1353550-13-6
Product NameOlmutinib

Biological Targets

EGFR

Associated Conditions

neoplasm·non-small cell lung carcinoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.

Critical reviews in oncology/hematology • Vol. 117 • 2017
PMID: 28807234DOI: 10.1016/j.critrevonc.2017.07.003

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

Journal of biomedical science • Vol. 23, Issue 1 • 2016
PMID: 27912760PMC: PMC5135794DOI: 10.1186/s12929-016-0305-9

HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.

Arthritis research & therapy • Vol. 18 • 2016
PMID: 27090981PMC: PMC4835877DOI: 10.1186/s13075-016-0988-z

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

Journal of hematology & oncology • Vol. 9 • 2016
PMID: 27071706PMC: PMC4830020DOI: 10.1186/s13045-016-0268-z

Documentation

Similar Products